What's new in HIV/AIDS? Neutralizing HIV antibodies: do they really protect?
Neutralizing antibodies work as a second line of defence. They are detected more or less in nearly every HIV-1-infected individual. 2G12, 2F5 and 4E10 represent antibodies with broadly neutralizing activity made from B cells of HIV- 1-infected humans. Unfortunately these antibodies are extremely rare and all attempts to elicit them via vaccine immunogens have failed. The discovery of autoreactive features of these antibodies could now explain why. Additionally, new results show the delayed viral rebound under antibody treatment in some HIV-1-infected individuals.
Jülg
B
B
Dept. of Infectious Diseases, Medical Policlinic, Ludwig Maximilian University Munich, Pettenkoferstr. 8a, 80336 Munich, Germany. Frank.Goebel@med.uni-muenchen.de
Goebel
F D
FD
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001323:Autoantibodies / Q000276:immunology; D002986:Clinical Trials as Topic; D015483:HIV Antibodies / Q000276:immunology* / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D009500:Neutralization Tests
D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D015483:HIV Antibodies